| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Luteolin-4'-O-glucoside targets multiple cellular pathways involved in oxidative stress, inflammation, and cancer. As a flavonoid, it acts as a potent antioxidant by scavenging free radicals and chelating metal ions. It may modulate the activity of enzymes such as cyclooxygenases (COX) and lipoxygenases (LOX), reducing the production of pro-inflammatory mediators. Luteolin-4'-O-glucoside also influences signaling pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to its anti-inflammatory and anti-cancer effects. The glycosylation at the 4'-position affects its bioactivity and bioavailability compared to the luteolin aglycone.
|
|---|---|
| ln Vitro |
NCI-H929, U266, and OPM2 cell lines are all susceptible to the cytotoxic effects of luteolin-4'-O-glucoside [3].
Luteolin-4'-O-glucoside exhibits antioxidant activity through DPPH, ABTS, and FRAP radical scavenging assays. It shows anti-inflammatory activity by inhibiting the production of nitric oxide, prostaglandins, and pro-inflammatory cytokines in LPS-stimulated macrophages. Luteolin-4'-O-glucoside also exhibits anti-cancer activity, including inhibition of cancer cell proliferation and induction of apoptosis. The compound's activities are generally lower than those of the luteolin aglycone due to the glycosylation. Specific IC₅₀ values for various activities depend on the assay system. |
| ln Vivo |
In vivo activity data for luteolin-4'-O-glucoside are limited in the available literature. Based on its in vitro antioxidant, anti-inflammatory, and anti-cancer activities, it is anticipated to have potential in vivo efficacy in models of oxidative stress, inflammation, and cancer. However, as a glycosylated flavonoid, it may have limited oral bioavailability due to poor absorption and extensive metabolism. Specific animal studies are not extensively documented.
|
| Enzyme Assay |
Non-cellular assays for luteolin-4'-O-glucoside typically involve measuring its antioxidant activity using chemical assays such as DPPH, ABTS, and FRAP. The compound's ability to scavenge free radicals is measured spectrophotometrically. Anti-inflammatory activity can be assessed using enzyme inhibition assays for COX-1, COX-2, and LOX. The compound is incubated with the enzyme and substrate, and the inhibition of product formation is measured. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for luteolin-4'-O-glucoside typically use macrophage cell lines such as RAW 264.7 to evaluate anti-inflammatory activity. Cells are treated with various concentrations of the compound, followed by stimulation with lipopolysaccharide (LPS) to induce inflammation. Nitric oxide production is measured using the Griess assay. Pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6) are quantified by ELISA. Cell viability is assessed using MTT assays to ensure that observed effects are not due to cytotoxicity. For anti-cancer activity, cancer cell lines are treated with the compound, and cell proliferation and apoptosis are assessed.
|
| Animal Protocol |
In vivo animal studies for luteolin-4'-O-glucoside are not extensively documented in the available literature. Based on its potential anti-inflammatory and anti-cancer activities, typical study designs would involve rodent models of inflammation or cancer. The compound would be administered orally or intraperitoneally. Inflammatory markers, tumor growth, and histopathological changes would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of luteolin-4'-O-glucoside are not characterized in the available literature. As a flavonoid glycoside with a molecular weight of 448.38, it is expected to have limited oral bioavailability due to poor membrane permeability and extensive first-pass metabolism. The glucose moiety may be hydrolyzed by intestinal glucosidases, releasing the luteolin aglycone. Metabolic pathways likely involve phase II conjugation (glucuronidation and sulfation) of the phenolic hydroxyl groups. Specific PK parameters such as half-life, Cmax, and bioavailability are not documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for luteolin-4'-O-glucoside are limited in the available literature. As a naturally occurring flavonoid glycoside, it is generally considered to have low toxicity. However, comprehensive toxicology studies are not available. The compound may cause skin and eye irritation upon contact. Standard laboratory safety precautions should be observed when handling this compound.
|
| References |
|
| Additional Infomation |
Luteolin 4'-glucoside has reportedly been found in Disporum cantoniense, Pseudognaphalium affine, and other organisms with available data.
Luteolin-4'-O-glucoside is a research-grade natural product intended for laboratory use only and is not approved for clinical use. Its CAS number is 6920-38-3. The primary applications of luteolin-4'-O-glucoside include studying the antioxidant, anti-inflammatory, and anti-cancer activities of flavonoid glycosides, investigating the effects of glycosylation on flavonoid bioactivity, and exploring the therapeutic potential of natural flavonoid glycosides. The compound is a valuable tool for natural product chemistry and pharmacology research. |
| Molecular Formula |
C21H20O11
|
|---|---|
| Molecular Weight |
448.3769
|
| Exact Mass |
448.101
|
| CAS # |
6920-38-3
|
| PubChem CID |
12304737
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.713g/cm3
|
| Boiling Point |
814.5ºC at 760 mmHg
|
| Melting Point |
210ºC (dec.)
|
| Flash Point |
288.5ºC
|
| Index of Refraction |
1.74
|
| LogP |
0.5
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
714
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UHNXUSWGOJMEFO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20O11/c22-7-16-18(27)19(28)20(29)21(32-16)31-13-2-1-8(3-10(13)24)14-6-12(26)17-11(25)4-9(23)5-15(17)30-14/h1-6,16,18-25,27-29H,7H2
|
| Chemical Name |
5,7-dihydroxy-2-[3-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2303 mL | 11.1513 mL | 22.3025 mL | |
| 5 mM | 0.4461 mL | 2.2303 mL | 4.4605 mL | |
| 10 mM | 0.2230 mL | 1.1151 mL | 2.2303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
